ArticlePloS one2013
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.Nature reviews. Clinical oncology · 2025Review
- Exploration of genes related to the development of cancer of unknown primary.Oncology reports · 2025Article
- Hypoxia induces radioresistance, epithelial‑mesenchymal transition, cancer stem cell‑like phenotype and changes in genes possessing multiple biological functions in head and neck squamous cell carcinoma.Oncology reports · 2022Article
- Review
- A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data.Frontiers in bioengineering and biotechnology · 2020Article
- TOOme: A Novel Computational Framework to Infer Cancer Tissue-of-Origin by Integrating Both Gene Mutation and Expression.Frontiers in bioengineering and biotechnology · 2020Article
- The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.Internal medicine (Tokyo, Japan) · 2019Article
- Clinical Outcomes in Patients with Cancer of Unknown Primary Site Treated By Gastrointestinal Oncologists.Journal of translational internal medicine · 2017Article
- Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.PloS one · 2015Article
- SpliceNet: recovering splicing isoform-specific differential gene networks from RNA-Seq data of normal and diseased samples.Nucleic acids research · 2014Article
- Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer.Journal of translational medicine · 2014Article
- Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targetingSignal transduction and targeted therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe biological basis for cancer of unknown primary (CUP) at the molecular level remains largely unknown, with no evidence of whether a common biological entity exists. Here, we assessed the possibility of identifying a common diagnostic biomarker for CUP using a microarray gene expression analysis.
methodsTumor mRNA samples from 60 patients with CUP were analyzed using the Affymetrix U133A Plus 2.0 GeneChip and were normalized by asinh (hyperbolic arc sine) transformation to construct a mean gene-expression profile specific to CUP. A gene-expression profile specific to non-CUP group was constructed using publicly available raw microarray datasets. The t-tests were performed to compare the CUP with non-CUP groups and the top 59 CUP specific genes with the highest fold change were selected (p-value<0.001).
resultsAmong the 44 genes that were up-regulated in the CUP group, 6 genes for ribosomal proteins were identified. Two of these genes (RPS7 and RPL11) are known to be involved in the Mdm2-p53 pathway. We also identified several genes related to metastasis and apoptosis, suggesting a biological attribute of CUP.
conclusionsThe protein products of the up-regulated and down-regulated genes identified in this study may be clinically useful as unique biomarkers for CUP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.